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The role of surgery in the management of malignant pleural mesothe-
lioma remains controversial. Surgical resection consists of different 
procedures for diagnostic or therapeutic reasons. The latter includes 
either an extrapleural pleuropneumonectomy (EPP) or lung-sparing 
operations like debulking of the parietal and visceral pleura by pleurec-
tomy/decortication (P/D) or extended pleurectomy/decortication, in 
which further debulking of the diaphragm or pericardium is included. 
Because of the modest outcome of surgery as single-modality therapy, 
combinations of chemotherapy, surgery, and radiation therapy were 
initiated as a new treatment strategy to improve prognosis. The obser-
vations that patients treated with P/D had an equal to better outcome 
than those treated with EPP, and that EPP with perioperative chemo-
therapy was better than EPP alone, raises the issue whether perform-
ing a P/D with perioperative chemotherapy would result in a further 
improvement of outcome with a lower operative mortality than with 
EPP and perioperative chemotherapy. This is the rationale for the next 
European Organisation for Research and Treatment of Cancer trial 
exploring the feasibility of P/D with perioperative chemotherapy.
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Malignant pleural mesothelioma (MPM) is a rare and aggressive disease arising from the pleural meso-
thelium, with a median natural history of less than 1 year.1 
Worldwide incidence rates are expected to increase and peak 
in the year 2020,2 although a leveling off has been observed 
in some industrialized countries.3 Only chemotherapy has 
been shown to improve the outcome significantly.4,5 In 2005, 
Maziak et al.6 systematically reviewed the surgical evidence 
from 32 studies and case series with either a retrospective 
or a prospective design. They did not retrieve randomized 
trials or guidelines, and the heterogeneity of the treatments 
administered precluded a pooling of the outcome data. The 
role of surgery hence remains controversial. In this article, we 
will review and interpret the key publications relating to the 
subject as a background of the next randomized phase 2 trial 
conducted by the European Organisation for Research and 
Treatment of Cancer.
SURGERY IN MPM
Surgery in mesothelioma can be performed for diagnos-
tic and therapeutic reasons.7–9 In the former, a gross biopsy of 
the pleura is obtained either by video-assisted thoracoscopic 
surgery or open (mini)thoracotomy. Therapeutic surgery in 
mesothelioma involves different procedures10:
1. Extrapleural pleuropneumonectomy (EPP) involves the 
“en bloc” resection of the parietal and visceral pleura 
with the homolateral lung, pericardium, and diaphragm 
and with repair of diaphragm and/or pericardium using 
synthetic patches. In a systematic review of 34 series in-
cluding 2462 patients from 26 institutions, median overall 
survival after EPP ranged from 9.4 to 27.5 months and 
median disease-free survival from 7 to 19 months.1 Re-
lapses do occur mostly locally suggesting incompleteness 
of resection. Overall perioperative mortality rates ranged 
from 0 to 12%, and overall perioperative morbidity rates 
ranged from 22 to 82%. Operative time ranged from 3.25 
to 6.5 hours and the duration of hospitalization from 8 to 
43 days. Despite these sobering figures, 45% of U.S. and 
23% of European thoracic surgeons still believe in cure by 
EPP alone.11
2. Lung-sparing procedures consist of the resection of the 
pleura without removing the lung. The procedure can be 
palliative to control fluid accumulation (pleurodesis by 
partial parietal pleurectomy) or aim at radicality when a 
cytoreduction of all macroscopic tumor on the parietal 
and visceral pleura is considered (pleurectomy/decortica-
tion [P/D]).7–9 In a systematic review of 1270 patients from 
26 reports on lung-sparing extirpative surgery, Teh et al.12 
found an operative mortality of 4% and average survival 
rates at 1, 2, 3, 4 and 5 year of 51, 26, 16, 11, and 9%, 
respectively. In addition, P/D was better than best sup-
portive care with a mean survival of 14 months versus 4.5 
months.13 Extended pleurectomy/decortication (e-P/D) is 
a promising new surgical procedure, which aims at maxi-
mal debulking with resection and reconstruction of the 
diaphragm and/or pericardium if necessary. An e-P/D can 
involve resection of a lobe, multiple wedges, or even a seg-
ment as long as it is lung sparing. Mortality and morbidity 
of this intervention are less in comparison with EPP, but the 
procedure currently suffers from a lack of standardization 
and uniformity.14,15
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MULTIMODALITY THERAPY
Because of the incompleteness of the resection as sin-
gle-modality therapy, combinations of chemotherapy, surgery, 
and radiation therapy were initiated as a new treatment strat-
egy to improve prognosis.16 Historically, the adjuvant strategy 
was explored first. Sugarbaker et al.17 reported on 183 patients 
from a retrospective single institutional series, treated with 
EPP followed by variable adjuvant chemotherapy regimens 
consisting of either doxorubicin or cyclophosphamide, with 
or without cisplatin, or carboplatin and paclitaxel. While the 
reported median overall survival time of 19 months and the 
5-year survival rate of 15% are within the previously reported 
range, subgroup analyses in different prognostic categories 
showed an impressive outcome in completely resected pN0 
epitheloid cases. It is, however, unclear whether these analyses 
were performed on intention-to-treat basis or merely reflects 
the survival of the fittest.18
In a retrospective series from three U.S. institutions, 
undergoing EPP with or without any kind of adjuvant treat-
ment, Flores et al.14 observed an improved outcome in those 
patients receiving adjuvant chemotherapy, postoperative 
radiotherapy (PORT), or both. Of the 384 patients who had 
either an EPP or P/D, 207 received adjuvant therapy, includ-
ing 130 who had radiation without chemotherapy, 35 who had 
chemotherapy without radiation, and 42 who received both 
chemotherapy and radiation. The type of surgical resection 
(EPP versus P/D) did not significantly influence the survival. 
The greatest survival difference was seen in patients who 
underwent multimodality therapy with surgery compared with 
patients who underwent surgery alone (median survival: 20 
versus 10 months). Patient and treatment selection may, how-
ever, account for the observed effect.19
A number of promising single institutional series with 
neoadjuvant chemotherapy resulted in the conduct of three 
prospective multicenter phase 2 studies of EPP in multimodal-
ity treatment (Table 1).20–22 The fraction of patients complet-
ing the planned treatment was 50 to 71%, and the fraction of 
patients completing the neoadjuvant chemotherapy and EPP 
was 74 to 84%. PORT was the biggest challenge to overall 
treatment time with a median duration of 184 days in one 
series, of which 30 to 84 days interval between the resection 
and the beginning of PORT.22 Quality of life was monitored 
in the Swiss study, where approximately 80% of the patients 
reported psychological morbidity, physical symptoms, and 
worsening of activity after surgery, followed by a recovery 
back to the baseline level.20
In a systematic review of 349 patients from seven 
series treated with EPP and any adjuvant treatment, Cao 
et al. observed a median overall survival of 13 to 24 months 
and a perioperative mortality of 0 to 11%. Presence of N2 
lymph node involvement is a significant prognostic factor as 
compared with N0 to N1 disease.1 In 286 patients treated with 
neoadjuvant chemotherapy and analyzed according to the 
intention-to-treat principle, they found a median overall sur-
vival for the intention-to-treat population of 14 to 25.5 months 
and a perioperative mortality of 0 to 7%, both in the same 
range as with the adjuvant strategy.1
MESOTHELIOMA AND RADICAL SURGERY
The controversy on the role and effectiveness of 
EPP in the management of MPM lead to the design of the 
Mesothelioma and Radical Surgery (MARS) trial.23,24 Patients 
were scheduled to receive three cycles of chemotherapy and 
to be restaged thereafter. Then, patients were assigned either 
to EPP followed by postoperative hemithoracic irradiation 
or to the no-EPP group, consisting of continued oncological 
management, which could include chemotherapy, palliative 
radiotherapy, or palliative surgery (pleurodesis). The EPP 
procedure was centralized in a limited number of participating 
high volume centers with experienced thoracic surgeons. To 
power this trial for the outcome of overall survival, an accrual 
of 670 patients was required. As the feasibility of allocating 
patients between a surgical and nonsurgical approach was 
questioned, a randomized phase 2 trial was first initiated in 
TABLE 1.  Prospective Multicenter Phase 2 Studies of Radical Multimodality Treatment in Early-Stage Mesothelioma
Variable SAKK trial20 U.S. trial21 EORTC 0803122
N/n institutions 61/6 59/11 77/9
Induction regimen Three cycles of cisplatin/
gemcitabin
Three cycles of cisplatin/
pemetrexed
Four cycles of cisplatin/
pemetrexed
Compliance to induction 
chemotherapy (%)
95 93 83
EPP 45 (74%) 42 (74%) 54 (70%)
Operative mortality (%) 2.2 6.5 7
PORT completed 36 (59%) 37 (65%) 40 (52%)
Median OS (ITT) 19.8 m 18.4 m 16.8 m
Median OS (PP) 23 m NA 29.1 m
Local relapse (% PP) NS 6 (16%) 11 (28%)
Median PFS (ITT) 13.5 m 13.9 m 10.1 m
Median overall survival 
time (days)
NS 184 NS
SAKK, Schweizerische-Abeitsgemeinschaft für Klinische Krebsforschung; EORTC, European Organisation for Research and Treatment of Cancer; EPP, extrapleural 
pneumonectomy; ITT, intention to treat; NA, not analyzed; NS, not stated; OS, overall survival; PFS, progression free survival; PORT, postoperative radiotherapy; PP, per protocol.
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50 patients.23 Of 112 patients registered over 3 year, only 50 
were randomized, because of incomplete registration, disease 
progression, or withdrawal by the patient. Despite obtaining 
informed consent before randomization, four patients changed 
their minds, another three patients refused EPP, and one patient 
randomized to the non-EPP group had EPP in a non-MARS 
center and died postoperatively because of multiorgan failure.
Survival was defined from time to randomization, this 
means after the induction chemotherapy. The patients allo-
cated to no-EPP had a better median and 1-year overall sur-
vival than those treated with EPP in the MARS trial and than 
those in a number of historical series.24 Quality of life was also 
worse in the EPP-treated patients and remained so during the 
2 years of follow-up.
The results of this feasibility trial have stirred the 
controversy even more than before, as the trial’s sample size 
was insufficient for outcome as primary end point and could 
only conclude to the nonfeasibility of a phase 3 trial on this 
issue.25,26 The enthusiasm to perform EPP declined in several 
institutions and a search for alternative surgical interventions 
revived.27
EPP VERSUS P/D
The observation that patients with MPM treated with 
lung-sparing surgical procedures did better than those 
 proceeding to EPP stems from different historical series 
(Table 2).14,28–38 A pooled series from three U.S. centers includ-
ing 663 patients with stages I–IV MPM demonstrated essen-
tially no survival differences, stage by stage, between P/D with 
a median survival of 16 months and EPP (12 months) with, 
however, higher local recurrence rate with P/D (65%) com-
pared with EPP (33%). Operative mortality was 7% with EPP 
and 4% with P/D. This was despite the observation that the 
group undergoing P/D was negatively selected as considered 
to have a worse prognosis and to be no candidate for EPP.14
Lang-Lazdunski et al.39 recently reported their pro-
spective series of 36 patients treated with e-P/D and hyper-
thermic pleural lavage with povidone–iodine followed by 
chemotherapy and compared them with similar patients 
treated with EPP. Median overall survival of 23 months in 
e-P/D patients was significantly better than the 12.8 months 
for EPP. Patients with epitheloid histology had a longer sur-
vival than the nonepitheloid ones. The survival benefit was 
regardless of stage. The mortality rate for EPP was 4.5% and 
for e-P/D was nil. Morbidity of e-P/D included prolonged 
air leak, empyema, reaccumulation of pleural fluid, wound 
infection, and bronchopleural fistulas. When patients had 
disease progression after P/D, most of them were still able 
to receive further systemic therapy as opposed to patients 
having had EPP, who were often too unwell to receive any 
active treatment.
Finally, a retrospective analysis of the International 
Association for the Study of Lung Cancer Mesothelioma 
database of 3101 patients of 15 centers from four continents 
showed no difference in the median survival time between 
EPP and P/D but in stage I patients in whom EPP was shown 
to result in a substantial survival benefit (40 months) com-
pared with 23 months for a P/D.38 With the caveats of the 
selection bias inherent to retrospective series, whereby fitter 
patients undergo more aggressive treatment and thus seem to 
achieve superior outcomes, these data suggest furthermore 
that patients receiving more than one treatment modality (that 
is surgery plus chemotherapy or radiotherapy) had a signifi-
cant better outcome.40
TABLE 2.  Extrapleural Pleuropneumonectomy and Pleurectomy/Decortication in Malignant Pleural Mesothelioma
Investigator (year)
No. of patients 
with EPP
No. of patients 
with P/D Chemotherapy Other modalities
MST EPP 
(months)
MST P/D 
(months)
Martini (1976)28 2 NS Adjuvant ± PORT 2 21
Branscheid (1991)29 76 82 Adjuvant − 9.3 10.4
Allen (1994)30 40 56 Adjuvant RTX 13.3 9.0
Pass (1997)31 39 39 NS Photodynamic therapy, 
immunotherapy
9.5 14.5
Pass (1998)32 25 23 NS Adjuvant immunochemotherapy 14.4 22
Rusch and Venkatraman 
(1999)33
115 59 ± adjuvant ± PORT 18.5 18.5
Martin-Ucar (2007)34 45 12 (Neo)adjuvant PORT 15 16
Flores (2008)14 385 278 Adjuvant PORT 12 16
Lucraz (2010)35 49 34 Adjuvant PORT 26 30
Lang-Lazdunski (2012)36 22 54 Neoadjuvant Hyperthermic pleural lavage, PORT 12.8 23
Rena (2012)37 40 37 (Neo)adjuvant 20 25
Rusch et al. (2012)38 1190 299 (Neo)adjuvant Various NS NS
p stage I 75 57 40 23
p stage II 229 77 23 20
p stage III 762 97 16 19
p stage IV 124 68 12 15
EPP, extrapleural pneumonectomy; IMRT, intensity-modulated radiotherapy; IORT, intraoperative radiotherapy; MST, mean survival time; NS, not stated; P/D, pleurectomy/
decortication; PORT, postoperative radiotherapy; RTX, radiotherapy.
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NOVEL STRATEGIES – WHERE DO WE GO 
AFTER MARS?
Since P/D has been repeatedly associated with similar 
to better outcome than EPP, and EPP accompanied by peri-
operative chemotherapy and radiotherapy was better than 
EPP alone, the question arises whether P/D as part of a mul-
timodality treatment further improves outcome (Table 2). The 
mechanism whereby P/D results in a better outcome than EPP 
remains unsolved. Some argue that the operative mortality, 
which is typically higher with EPP, is the cause. Others specu-
late that a maximal cytoreduction is not necessary because 
survival rates are determined by the time before the relapse of 
MPM. Comprehensibly, lung-sparing surgery can be respon-
sible for better survival rates. P/D patients tend to recur more 
locally, and these relapses can be retreated either surgically or 
by radical radiotherapy, suggesting that the improved outcome 
of P/D might be related to this relapse pattern. However, the 
data of P/D as part of a multimodality treatment are mostly 
extracted from retrospective selected series spanning sev-
eral decades, with different drugs, not analyzed according 
to the intention-to-treat principle and require prospective 
confirmation.
The UK investigators will investigate the role of 
extended P/D in a “MARS-2” trial wherein this surgical pro-
cedure will be added to standard induction chemotherapy 
and randomly compared with chemotherapy only.41 The Lung 
Cancer Group of the European Organisation for Research and 
Treatment of Cancer will conduct a randomized phase 2 trial 
in patients with early-stage MPM randomizing between four 
cycles of neoadjuvant chemotherapy (cisplatin/pemetrexed)
followed by P/D or P/D followed by four cycles of the same 
chemotherapy given in adjuvant setting (Fig. 1).42 This study 
will evaluate whether immediate or deferred P/D in combina-
tion perioperative chemotherapy is feasible and safe. Primary 
end point is the rate of success being defined as any registered 
patient who has received four cycles of chemotherapy and has 
undergone P/D and is alive at 20 weeks after registration with-
out evidence of progression, relapse, or toxicity higher than 
grade 3 according to the Common Toxicity Criteria. To power 
this study at 90% a sample size of 64 patients is necessary, 
32 in each arm. It is hoped that both these trials will allow 
to clarify the role of P/D before embarking on the necessary 
phase 3 in which EPP and P/D are compared.
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